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Abstract
The benefit of hyperthermia as a potent modifier of radiotherapy has been well established and more recently
also the combination with chemotherapy was shown beneficial. Also for head and neck cancer, the impact of
hyperthermia has been clinically demonstrated by a number of clinical trials. Unfortunately, the technology applied in
these studies provided only limited thermal dose control, and the devices used only allowed treatment of target
regions close to the skin. Over the last decade, we developed the technology for deep and controlled hyperthermia
that allows treatment of the entire head and neck region. Our strategy involves focused microwave heating combined
with 3D patient-specific electromagnetic and thermal simulations for conformal, reproducible and adaptive
hyperthermia application. Validation of our strategy has been performed by 3D thermal dose assessment based
on invasively placed temperature sensors combined with the 3D patient specific simulations. In this paper, we
review the phase III clinical evidence for hyperthermia in head and neck tumors, as well as the heating and
dosimetry technology applied in these studies. Next, we describe the development, clinical implementation and
validation of 3D guided deep hyperthermia with the HYPERcollar, and its second generation, i.e. the HYPERcollar3D.
Lastly, we discuss early clinical results and provide an outlook for this technology.
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Introduction
In current clinical practice, tumors of the head and
neck (H&N) region are treated with surgery, radiother-
apy (RT), chemotherapy or combinations of these. Early
cases are usually treated with either surgery or RT,
where locally-advanced primary carcinoma of the H&N
are treated with RT, often combined with chemotherapy
[1]. Following the introduction of hyper-fractionation
schedules of RT and technological improvements like
intensity modulated RT (IMRT), higher tumor dose and
reduction of some toxicity endpoints, such as xerosto-
mia [2], can be achieved but the toxicity remains sub-
stantial [3, 4]. In 2000, Pignon et al. [5] published a
three meta-analyses study, which showed that combin-
ing RT with simultaneous chemotherapy on average re-
sults in an 8 % absolute increase of the overall 2-years
survival. More recently they observed a 4.5 % absolute
benefit at 5-years in another meta-analysis involving 87
trials [6]. Still, improvement is warranted since loco-
regional recurrence rates are up to 30–60 % after complex
multimodality treatment [7]. In addition, more than
80 % of patients experience severe toxicity with current
regimens, as well as enduring long-term effects from
treatment, relapse, or metastasis [1]. For chemotherapy,
the reported improved treatment outcomes were ac-
companied by enhanced systemic toxicity or exacerbate
local tissue reactions, while accelerated fractionation
causes high rates of severe mucositis resulting in early
stoppage of randomized trails [8]. Hence, this combin-
ation often is too toxic, in which RT alone provides a
2-years loco-regional control of only 50 % and an over-
all survival of 53 % [6]. In recurrent H&N cancer, 80 %
of patients are not eligible for a curative treatment and
local tumor control after retreatment is only 26–52 %
[9, 10] leading to a 2-years overall survival of 10–20 %
for reirradiation and chemotherapy [11]. Moreover,
toxicity after re-treatment with concurrent irradiation and
chemotherapy is even more severe (grade four toxicity
18–23 %, and grade five toxicity 5–8 %) [11, 12]. Hence,
as most patients die because of local treatment failures,
there is a need for improved loco-regional treatment.
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Biological research showed that hyperthermia (HT),
elevation of the tumor temperature to 40–44 °C for
60–90 min, is amongst the most potent modifiers of RT
known today [13]. In addition, HT also enhances the ef-
fect of many chemotherapies [14]. The impact of HT
without inducing extra toxicity was clinically demon-
strated by a number of clinical trials, including four
studies in H&N cancer. Unfortunately the technology
used in these studies allows heating of only superficial
regions. In addition, the technologies and strategies ap-
plied provide limited control of the applied thermal
dose. This makes it difficult to reproduce the results or
to quantify the level of temperature rise or thermal
dose required [15]. Hence, although these trials demon-
strated statistically significant outcomes, the clinical
objective in terms of required temperature or thermal
dose cannot be quantified. This forms a hurdle to re-
produce the applied dose, which hampers progress
through follow-up clinical trials and dissemination of
the treatment to other clinics. Therefore, over the last
decade, we developed technology to apply deep HT to
all regions in the H&N region, while in the meantime
also providing the most objective and reproducible
treatment strategy achievable. In this way, the means
are provided to mature and popularize the application
of deep HT in H&N cancer.
The current publication provides an overview over the
results obtained in phase III clinical studies and reviews
the equipment and dosimetry applied. Next, we review
the development, clinical implementation and validation
of simulation guided application of deep HT to target re-
gions in the H&N region using the Rotterdam approach.
Hereto, we summarize the technology developed (the
two applicator versions and treatment planning), the
clinical experience and heating quality obtained and the
early clinical outcomes.
Review
Status quo in head and neck hyperthermia
There are four prospective randomized phase III trials
that demonstrate the effectiveness of HT in H&N tu-
mors. Table 1 summarizes the results per study, where
more extensive reviews concerning the clinical results
are provided in [16, 17]. In addition, we summarize the
most important study, heating and dosimetry details for
these studies. Lastly, we included the results of the most
recent study by Datta et al., whom overviewed the re-
sults of not only these four randomized phase III trials,
but also included well-controlled non-randomized trials
on HT for several tumor sites, including the H&N.
Valdagni et al. [18, 19]
Study design: Fixed, inoperable and previously untreated
metastatic lymph nodes, from a H&N or unknown pri-
mary, were randomized to receive RT or RT combined
with HT. In total, 44 N3 metastatic lymphnodes in 41 pa-
tients were included and the randomization was per-
formed per individual node. Fractions of 2.0–2.5 Gy
were applied five times per week to a total dose be-
tween 64–70 Gy, average dose was 68 Gy for RT alone
and 67.5 Gy for RT + HT. In the combined treatment
arm, nodes were further randomized to receive two or
six heat sessions: either two sessions of HT in the first
week of radiation or six sessions in the first three weeks
of radiation. Heat sessions were applied 20–25 min
after RT, with an interval of at least 72 h between sub-
sequent heat sessions.
Outcomes: In an interim analysis, prematurely a signifi-
cant improvement in complete response rate after RT +
HT was seen versus RT alone, 82.3 % vs 36.8 % (p =
0.0164). Note that, since the study was prematurely closed
for ethical considerations, the number of patients accrued
was limited. Follow-up analysis showed that the statisti-
cally significant difference between “early” response rate in
Table 1 Results of randomized phase III trials on hyperthermia for cancers in the head and neck
Reference Tumor Combi N Endpoint(s) -HT +HT Heating Quality control
Valdagni et al.
1988 & 1994 [18, 19]
Neck Nodes RT 44 CR 41 % 83% Radiative
(280–300 MHz)
Invasive, > 4 each HT
session (periphery:core = 4:1)
5 years LC 24 % 69%
5 years OS 0 % 50%
Datta et al. 1990 [21] OC, OP
(stage I–IV)
RT 65 CR 31 % 55 % Capacitive, (27.12 kHz) -
Huilgol et al. 2010 [22] OC, OP, HP
(stage II–IV)
RT 54 CR 42 % 79% Capacitive (8 MHz) Invasive (infrequent)
Hua et al. 2011 [25] NP
(stage I–IV)
CRT 180 5 years LC 79 % 91% Conduction (resistive wire) Nasal cavity internal
skin temperature
5 years PFS 63 % 73%
5 years OS 70 % 78 %
Zhao et al. 2014 [27] NP
(stage II–IV)
CRT 83 3-years OS (QoL) 54 % 73% Capacitive Nasal cavity internal
skin temperature
RT Radiotherapy, CRT Chemo-radiotherapy, N total number of included patients in the study, −HT results without HT, +HT results with HT, LC local control, CR
complete response, PFS progression free survival, OC oral cavity, OP oropharynx, HP hypopharynx, NP nasopharynx. Results in bold are significant at the 5 %-level.
Toxicity was comparable in all randomized trials, although Zhao et al. found an improved quality of life (QoL)
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the two arms translated into a similarly significant long-
term difference in actuary nodal control (p = 0.015) and 5-
year survival rate (p = 0.02) [19]. They also randomized
between two and six heating sessions in the combined HT
and radiation group. A small trend towards six sessions,
but no significant advantage could be demonstrated. In
this study, the addition of heat did not result in any en-
hancement of early or late side effects on normal skin, the
only exception being one blister as a consequence of super-
ficial overheating because of metastatic skin involvement.
Second study: In addition to previous study using the
same scheduling, Amichetti et al. [20] showed in a I/II
trial that HT also improves treatment outcome when
added to a hyper-fractionated radiation schedule.
Heating and QA: Superficially located metastatic
lymph nodes were heated using radiative microwave
heating using the MA 150 applicator (280–300 MHz,
aperture size 10 x 13 cm) of the BSD 1000 system (BSD
Medical, Salt Lake City, USA). For each treatment, in-
vasive thermometry was performed using multipoint
Bowman thermal probes in a minimum of five intra
and peritumoral locations and on a minimum of three
sites on the skin. Twelve thermal probes were select-
ively inserted into tumor-normal tissue interfaces, with
a nodal periphery-nodal core ratio of approximately 4:1.
Thermal mapping along the probe axis was occasionally
performed. Probe localization and verification was mostly
determined from orthogonal x-ray films. The goal for each
session was to attain a tumour temperature of at least
42.5 °C per 30 min at the periphery of the target volume.
Datta et al. [21]
Study design: Sixty-five patients were included in a
randomized clinical study to evaluate the efficacy of local
HT as a concomitant agent to RT. Primarily advanced
tumors were included, but the majority of those were
close to the skin and 14/33 tumors in the cheek. All the
patients were treated with 50 Gy telecobalt therapy in
5 weeks by using two parallel, opposed fields encom-
passing the primary and the regional lymphatics. A boost
of 10–15 Gy in 5–10 days was given to the gross tumor
volume. Ten HT sessions were applied to the gross
tumor volume twice a week with a period of 72 h be-
tween the two sessions. RT was applied immediately
after heating.
Outcomes: Overall no significant increase in response
rate was observed. In patients with Stage I and II, re-
sponse was similar, while patients with advanced dis-
ease (Stage III and IV) had a significantly better
tumour control after the combined treatment. Compli-
cations, especially skin and mucosal reactions, of both
groups were almost identical in type and magnitude.
Heating and QA: Capacitive heating at 27.12 kHz was
applied by the Siemens Ultraterm 607E diathermia ma-
chine. Two rubber pad electrodes were placed on either
side of the tumour with a felt pad placed between skin
and electrode to act as a coupling medium. Thermom-
etry was measured using a thermocouple placed in the
center of the tumour and measuring at 15 min intervals
while switching off the heating device. Power was in-
creased until a temperature of 42.5 ± 0.5 °C was achieved,
which was maintained at least 20 min.
Huilgol et al. [22]
Study design: A total of 56 patients with cancers of
the oropharynx, hypopharynx and oral cavity were ran-
domized to receive either RT or RT–HT. Primarily T3-
T4 stages were included and all patients were treated
with radiation to a dose of 66–70 Gy in 6.5–7 weeks.
Patients in the study group were treated with weekly
30 min HT applied after RT at an unknown interval.
HT was stopped if patients developed grade II or higher
thermal burns.
Outcomes: Complete response was seen in 42.4 % of
RT alone group compared to 78.6 % in the HT group
(p < 0.05). Twenty-three patients could finish more than
five sessions, where five dropped early due to pain or
systemic stress. Overall, acute and late toxicities were
comparable in both treatment arms except for an over-
all increase of thermal burns in the HT group.
Heating and QA: HT was delivered on modified Ther-
motron RF-8 (Vinita Yamamoto Inc., Japan), operated at
frequency of 8 MHz. Ten minutes precooling was ap-
plied before starting HT. Guided by visible tumor or
anatomical landmarks, both antennas were placed on
each side of the neck. After impedance matching, power
was gradually escalated till the patients complained of
unbearable pain, stress or discomfort. Power was then
reduced and maintained till completion of the treatment.
Input power varied from 400 to 1000 kW. Patient spe-
cific quality assurance was not performed, but in some
patients an average temperature in the tumor of 42.3 °C
was reported as measured using invasive thermometry
with a thermistor probe. In addition, the performance of
the applicator was investigated [23]. These experiments
showed that this device provides an option for lateral tu-
mors but not deeply located, i.e. despite the facts that
the phantom cylinder was much smaller than that in
other studies (10 cm vs 12–15 cm [24]), that fat was not
modelled and vicious cooling was applied, still substan-
tial heat was absorbed only in superficial tissues.
Hua et al. [25]
Study design: In total 180 patients presenting with naso-
pharyngeal cancer were randomized to receive (chemo)-RT
with or without HT. A total dose of 70 Gy was adminis-
tered to the primary tumour and the upper neck in 2Gy
fractions, with or without a boost applied using brachyther-
apy. Lymphnode levels were always irradiated by at least
50 Gy and clinically positive neck nodes received a mini-
mum dose of 60 Gy. RT was delivered daily, five times a
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week. All T3 and T4 tumors were treated with concurrent
chemotherapy consisting of cisplatin and 5-FU. HT was ap-
plied to the tumor once a week within 30 min before or
after RT, for a total of seven times, or 2 h after cisplatin
finished.
Outcomes: This study demonstrated a significant im-
proved CR, i.e. 81.1 % (CRT) to 95.6 % (CRT +HT) (p =
0.003). After 5-years local control (p = 0.022) and PFS
(p = 0.039) were significant but OS was not significant
(p = 0.14). Subgroup analysis indicated that RT was
already sufficient in for T1 tumors, but that HT had a
significant contribution to local control of T2/T3 cases,
although no significant overall survival advantage could
be demonstrated. Possibly because tumors with skull
base invasions were excluded and their consequent low
number, no significant improvement for T4 tumors
could be established. However, the average improve-
ment by HT was also smaller, which suggests problems
in achieving sufficient temperatures in these larger
tumors. The most common toxicities were local muco-
sitis, erythema, and blisters, but acute oral mucous tox-
icity in both arms was comparable and no lethal toxicity
occurred. Late adverse reaction was comparable in the
HT group.
Heating and QA: Specifically designed intracavitary
equipment was used based on a commercially available
device (WE2102-A Microwave HT System, Yuan De
Biomedical Engineering, Beijing). The technique employed
was mentioned to be 915 MHz microwave radiation [25],
but the reply to a letter to the editor [15] mentions a hot
wire based conductive heating technique [26]. Patient spe-
cific quality assurance was performed in this study by
measuring the temperature of the nasal cavity mucosa
using a thermocouple temperature sensor. In addition, an
experiment with a beagle dog was performed to relate skin
temperatures around 43 °C to temperatures 3 cm into the
mucosa 42.7 °C. Unfortunately, it remains unclear if the
dog was anaesthetized, possibly leading to a downregu-
lated thermoregulatory response and higher temperatures
achieved.
Zhao et al. [27]
Study design: In total 83 patients presenting with naso-
pharyngeal cancer were randomized to receive (chemo)-
RT with or without HT. First,
chemotherapy (paclitaxel 135–175 mg/m2, cisplatin
60–90 mg/m2, every 3 weeks, for two cycles) was given.
Second, the physical condition of the patients was evalu-
ated. One week later, patients received 2 Gy fractions
conformal radiation therapy (3D-CRT) to the cervical
lymphnodes (5 weeks, 50Gy) and to the nasopharynx
target (7 weeks, 70–74 Gy). All patients received con-
comitant chemotherapy (cisplatin 30 mg/m2, once a
week). Third, patients received chemotherapy (paclitaxel
135–175 mg/m2, cisplatin 60–90 mg/m2, every 3 weeks
for four cycles). Patients randomly selected for the study
arm received capacitive HT for one hour every other day
after RT, for a total of 21 times in 7 weeks.
Outcomes: The 36-month survival rate was 73 % for
CRT + HT compared to 54 % for CRT (p = 0.041). The
average disease-free survival time was 48 months ver-
sus 37.5 months in the reference arm (p = 0.048). In the
post-treatment questionnaires, several NPC-specific
treatment side effects (pain, swallowing, speech, social
eating, opening mouth, dry mouth, sticky saliva) were
asked. These quality of life (QoL) domains were better
preserved with CRT + HT compared to CRT at different
time-points.
Heating and QA: In this study, the commercially avail-
able HG-2000-type non-invasive
capacitive radiofrequency applicator (Zhuhai Hokai
Medical Instruments, Guangzhou, China) was used. The
frequency of this devise is reported to be 13.56 MHz or
40.68 MHz. The diameter of the primary plate was
0.8 cm, the length 1.5 m; and the maximum output power
was 1200 W. The temperature in the tumor was estimated
by measurements at the internal skin surface. Power was
increased from 100–150 W every 10 min by 10–20 W
steps until the surface temperature reached 43 °C.
Overview of four randomized and four non-randomized
studies: Datta et al. [28]
Study design: An overview of the status quo on HT in
terms of response rate for (chemo)-radiation with or
without HT [28]. For the H&N, this study included in
total 717 patient from four of the above mentioned ran-
domized phase III studies, and four non-randomized
studies for which representative historical control groups
were available.
Outcomes: This review demonstrated a statistical sig-
nificant difference (p < 0.001) in favor of the HT group,
i.e. complete local response was 50.3 % (183/364) for
(chemo)-radiation versus 75.3 % (266/353) for (chemo)-
radiation combined with HT, with an odds ratio of 3.71
(95 % CI, 2.55–5.38).
Heating and QA: In 2/8 studies, intracavitary HT was
used by exploiting either resitive wire or microwave HT.
3/8 studies used capacitive HT at frequencies between 8
and 13.56 MHz. In 3/8 studies, radiative HT was applied
at frequencies between 280 and 915 MHz, although of
one study the frequency could not be traced. Besides the
quality assurance described above, no invasive thermom-
etry was used to control the heating.
In summary, there is accumulating evidence that HT
improves radiation and chemotherapy in H&N cancers.
In addition, no extra toxicity has been observed. One
study even showed an improvement in RT affected qual-
ity of life (QoL). Still improvements are warranted be-
cause the commercially available applicators only
provide heating of lateral tumors while adequate heating
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of the complete CTV, i.e. tumor and lymphnode stations
affected and/or at risk, usually requires heating large re-
gions that can also extend to regions deeper than 4 cm
from the skin. Note that, although current trials have
shown the greatest benefit in large-hypoxic-tumors, HT
may also have great future potential specifically in this
CTV-GTV margin due to its selective effect on tumor
cells stemming from the sequential application of RT
and HT [29].
Since the application of HT in the phase III trials is
characterized by very limited monitoring and control of
the applied thermal dose, it is difficult to reproduce the
results, or to quantify the level of temperature rise or
thermal dose required. Hence, although these trials dem-
onstrated statistically significant outcomes, the clinical
objective in terms of required temperature or thermal
dose has not been established. Consequently, progress
through follow-up clinical trials has been poor and dis-
semination of the treatment to a larger group of clinics
was hampered.
To overcome the hurdles of deep heating and control,
over the last decade, we developed technology to apply
deep HT to the CTV combined with the most objective
and reproducible treatment strategy achievable based on
pre-treatment planning simulations.
Equipment for controlled deep hyperthermia in the
head and neck
The HYPERcollar: in use from 2007–2014
The design of the HYPERcollar (Fig. 1) differs from his-
toric design approaches in the fact that we worked
inverse. That is, we first defined the target volume to
be heated and then relied completely on theoretical
modeling to design the applicator to meet the defined
objectives in terms of power absorption, expressed in
the specific absorption rate (SAR, W/kg). An important
advantage of this approach is that a priori the translation
of predicted SAR distributions for such theoretically de-
signed applicators have a much higher probability to re-
semble the actual SAR distribution in vivo, than existing
devices where the electromagnetic model of the applicator
was drafted afterwards. For the design of the HYPERcollar,
extensive parameter studies were performed starting with
a simple arrangement and stepwise increasing the com-
plexity of the model. We showed that frequencies in the
range of 400 to 600 MHz can focus energy efficiently into
the center of the neck and selected 434 MHz as best com-
promise [24, 30]. At this frequency, increasing the number
of antennas and antenna rings led to a better focusing of
the power [31, 32]. To enable heating patients of vari-
able size with a centrally located tumor, i.e. the worst-
case scenario, we selected an arrangement consisting of
two rings of six antennas with a radius of 20 and 6 cm
spacing between the two ring arrays of applicators. A
crucial step in the HYPERcollar applicator design was
to replace the dipole antennas for a resonant patch an-
tenna [33]. The direct feeding of the patch antenna by a
coaxial cable without requiring a matching circuit leads
to greater robustness and higher efficiency, but also
easier and more accurate modeling. Consequently, the
predicted results were in very good agreement with the
experimental results, for the electrical performance as
well as the SAR distributions [31]. SAR validation was per-
formed with a specially constructed laboratory prototype
H&N applicator, including a neck mimicking cylindrical
muscle phantom [24]. Using phase steering, we showed
that the antenna arrangement enables to adjust the SAR
focus in radial (x/y) and axial (z) directions. A central
50 % iso-SAR focus of 35 mm (±3 mm) in diameter and
approximately 100 mm (±15 mm) in length were obtained
for all investigated settings. For the HYPERcollar, we
found identical values [31] and demonstrated the ability of
the HYPERcollar applicator to adequately deposit micro-
wave energy in the target region in a simulation study
using a representative clinical case [34].
The HYPERcollar3D: in use since 2014
The clinical experience obtained with the HYPERcollar
revealed crucial information on how to proceed in tar-
geted heating of H&N tumors [35]. Unbiased observa-
tions of the use of equipment and protocols and
interviews with different stakeholders, i.e. patients, tech-
nicians, physicists and medical doctors, were used to re-
veal demands or latent needs. We found that a major
item in fast, accurate and comfortable application of
H&N HT, especially simulation guided, is the control-
lable and reproducible positioning of the patient which
proved difficult using the HYPERcollar [35]. Addition-
ally, the shape of the water bolus was difficult to repro-
duce while we found that it has strong effects on the
Fig. 1 The HYPERcollar applicator, as it was used until 2014,
surrounding the 1st author. This applicator features twelve antennas
fed by a high power system with twelve channels with independent
power and phase control for focusing the heat at the target region
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treatment performance with respect to the maximum
applicable RF-power, the reflected power for some spe-
cific antenna’s, and the occurrence of superficial hot
spots. Finally, the applied amplitude and phase settings
revealed that the SAR distributions could be improved
by optimizing antenna positions. Therefore, we fully
redesigned the HYPERcollar, leading to the HYPERcol-
lar3D [36], of which the most improvements are:
Patient positioning: In the new design (Fig. 2), patient
positioning has been improved by implementation of a
standardized headrest, as used in RT, combined with a
laser alignment system to enable accurate reproduction
of the position during the planning CT. Tests with five
volunteers demonstrated that this procedure facilitates a
positioning accuracy (full-range) of ±2 mm (ventral-dor-
sal), ±4 mm (cranial-caudal) and, although not validated,
an estimated ±4 mm (left-right) [37].
Waterbolus: The HYPERcollar3D design utilizes a
smaller antenna-skin distance, splitting functionalities in
an inner (flexible) and outer (stiff ) waterbolus to sub-
stantially improve waterbolus shape robustness. To ac-
count for the differences in anatomy, the flexible part of
the bolus can be replaced by other inserts to enable
treatment of tumors in the neck (convex) as well as in
the head (concave). The improvements were validated
using a specifically designed mock-up applicator and CT
scanning was used to verify that the waterbolus closely
conformed to the skin contour. In addition, a high reso-
lution infra-red camera was used to show that the
temperature in the waterbolus was homogeneous,
which demonstrates the homogeneity of skin cooling.
Hence, this modular and predictable waterbolus shape
substantially improves the accuracy of translating HTP
from screen to patient.
Antenna array arrangement: Simulation studies in
SEMCAD-X (version 14.8.5, Schmid & Partner Engin-
eering, Zurich, Switzerland), and 3D patient models of
26 patients treated with H&N HT, were used to analyze
the predicted HT treatment quality (hotspot target
quotient: HTQ [38]) for various antenna array arrange-
ments [39]. We showed that a higher number of anten-
nas (20 vs 12), and their repositioning, provides a
substantial reduction of hot-spot importance, i.e. HTQ
reduces by 32 %. In addition, an average of 981 W can
be used, which drastically reduces the probability for
system power to become a treatment limiting source.
Combined, these improvements result in a predicted
two-fold increase in SAR level that can be clinically ap-
plied to the target [39].
In summary, the HYPERcollar3D provides accurate
patient positioning and improves water bolus (WB)
shape stability and tissue connection. Combined, the im-
provements in positioning and the more reproducible
waterbolus shape improve the translation of simulation
settings into the clinic, which improves the SAR focus-
ing and makes the simulation guided HT more effective.
Besides improved accuracy, the renewed positioning
strategy also allows for quicker patient positioning and
increased patient comfort. Note that a comfortable pos-
ition is not only desired from a comfort point of view
but also aids in a reproducible positioning.
Applicator modelling and quality assurance
Simulation accuracy is always critically dependent on a
sound implementation of the applicator into the electro-
magnetic simulator. Hence, extensive validation of the
model is required to match the performance of the ap-
plicator in the simulator and in reality.
These 3D CAD implementations are also used in the
HTP process to predict the electric field, and hence the
SAR distribution when the fields of antennas are com-
bined, for each patient [36]. During the development of
the HYPERcollar and HYPERcollar3D, we already devel-
oped and validated the EM implementation of these
Fig. 2 a Design and (b) clinical prototype of the HYPERcollar3D applicator. Twenty antennas are arranged in three rings to allow more precise
longitudinal steering, as compared to the HYPERcollar applicator. In addition, positioning reproducibility and waterbolus shape stability was
improved to improve the focusing ability and reproducibility of the applicator, and hence the treatment. Note that still a high power system with
twelve channels is used and hence a dedicated antenna selection procedure was developed
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applicators. In addition, stable performance of the appli-
cator over time must be verified to ensure the predictive
value of the simulator, and hence the effectiveness of a
simulation guided treatment strategy. Simultaneous to
the development of the HYPERcollar3D, we therefore
also extended our quality assurance protocol. Initially,
quality measurements were performed by measuring
the electric field sensors and infra-red thermometry
(temperature increase profile) using a split-phantom
[31]. Hereto, we developed a dedicated setup for 3D
scanning of the electric field distribution produced by
the applicator [40]. In this way, the 3D electric field dis-
tribution can be measured in tissue simulation liquids
inserted into a cylindrical “neck-sized” casing with a
diameter of 15 cm. This procedure is still under develop-
ment, especially obtaining a realistic waterbolus shape is
cumbersome, but already a match between measurement
and simulations better than 10 % in electric field was
obtained. By comparison of the normalized root-mean-
squared measured and simulated electric field distribu-
tions, we showed that the measurements qualitatively
matched very well to the simulations for the HYPERcol-
lar3D, i.e. the maximum SAR could be predicted < 5 mm
accuracy. Still, initial measurements did not fulfill our
gamma criterion (dose difference < 10 %, distance to
agreement < 10 mm). Note that disagreements were at
locations outside of the volume of interest, i.e. in the re-
gion beneath the waterbolus edge. However, by using the
3D reconstruction of the waterbolus shape, a better match
between simulations and measurements was obtained
leading to approval for clinical use [41].
High-power amplifier and control system
In so called “phased array applicators”, like the HYPER-
collar and HYPERcollar3D, the most important treat-
ment parameters to be optimized are the properties of
the microwave signals applied to the antennas, i.e. the
power and phase of the signals supplied by the high
power amplifier and control system. Hence, very import-
ant in our simulation guided approach is an accurate
transfer of optimized signals into the clinical situation.
Therefore, we developed and rigorously tested a
433.92 MHz multi-channel amplifier system with accur-
ate control over the amplitudes and phases applied to
the antennas [42]. The design consists of a direct digital
synthesizer (DDS) system that generates 12 phase-
controlled coherent 433.92 MHz signals, which are
amplified to maximum 200 W output per channel. Dir-
ectional couplers are placed at the amplifiers to couple
a small portion of both forward and reflected signals to
gain-and-phase detectors. The power setting is applied
with a resolution of 2 W and for the phase it is 0.1°. In
addition, the sampling rate of 100Hz also allows fast
switching approaches to homogenize the heating pattern.
The performance of the designed amplifier system was
tested by measuring the RF spectrum, power and phase
accuracy, and by characterizing the feedback control. The
measurement accuracy for the power (< 5 %) is valid for at
least 20 days after calibration and for the phase (< 5 °) it is
valid for at least 2 months. Hence, this system provides
the required technology for accurate conversion of opti-
mized settings into the clinic.
Pre-treatment planning
HT treatment planning (HTP) is the process of deriving
a 3D patient model and using 3D electromagnetic and
temperature simulation tools to optimize treatment pa-
rameters such that the best achievable temperature pat-
tern in the clinic is obtained [43]. Simulation studies
have shown that HTP is an absolute requirement for
clinical use of the HYPERcollar [34]. The latter is even
more emphasized as in general, interstitial thermometry
in H&N tumors is in 70 % of cases deemed not feasible
[35]. The required catheters that are inserted into tissue
are a burden to the patient and their discomfort leads to
their removal usually after one or two sessions [44]. In
addition, the temperature measurement probes inserted
into these catheters, even when applying multi-sensor
probes, provide only limited sampling of the temperature
distribution. Hence, it is clear that optimizing HT treat-
ment quality on temperature measurements alone has a
poor potential. This is why, from the start of H&N HT
we have focused on using HTP not only for treatment
optimization, but also for dosimetry purposes. Hereto
we developed VEDO (Visualizer for Electromagnetic
Dosimetry and Optimization, Fig. 3) [36]. Based on the
electric field and tissue distribution generated using
dedicated HTP simulation software, like Hyperplan or
SEMCAD-X, VEDO can optimize treatment settings to
maximize the cubic filtered SAR (cf-SAR: [36]) in pre-
treatment planning. In addition, VEDO provides real-
time re-optimization possibilities for adaptive applica-
tion of HT.
Patient modelling
A major element in an accurate simulation of the SAR
distribution is the accuracy of the patient model. Al-
though new strategies are underway that allow creation
of inhomogeneous patient models [45], tissue volumes
are segmented using a computed tomography (CT)
scan in our current protocol. Literature based homoge-
neous properties are assigned to these tissue volumes
to create a 3D dielectric property distribution. Initially,
the segmentation process for normal tissues was semi-
automatic, i.e. areas of exterior, fat, muscle and bone were
segmented automatically and tissues such as cartilage,
white matter and grey matter were manually discrimi-
nated. This process took 6–8 hours for a complete 3D
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model. Therefore, we developed a software tool that uses
the information of earlier segmentations for discriminat-
ing tissue types for the CT of the patient to be treated
[46]. We showed that segmentation accuracy of this auto-
matic procedure falls within the variation observed when
a CT scan is segmented by different observers. By a simu-
lation study, we showed that the uncertainty of SAR pre-
dictions caused by segmentation errors can be neglected
in the total modelling uncertainty [47]. In addition, we
studied if simulation accuracy can be improved by incorp-
orating also the information from magnetic resonance im-
aging (MRI). Hereto, we developed a dedicated matching
tool to align the CT and MRI scans [48], and extended
and validated the auto-segmentation tool [49]. Next, using
a simulation study, we showed that additional segmenta-
tion detail is not important for the signal optimization
[50]. However, when predicting the SAR in organs at risk,
the number of segmented tissues was shown relevant, i.e.
a difference in maximum SAR of 10.9 % was predicted for
CT-based (homogeneous) brains versus MRI-based (white
matter, grey matter, cerebral spinal fluid) modelling [51].
Moreover, in specific cases, segmentation detail was re-
quired to accurately predict hotspots [50].
In addition to segmentation of normal tissues, also the
tumor tissue must be delineated since it has different
EM and thermal properties. In current clinical practice,
this is done manually. From the beginning, we have fo-
cused on resembling the RT treatment, and hence the
imaging and patient positioning during the HT treat-
ment. This allows to directly take over the delineation of
the target volume. Initially, only the clinical target vol-
ume (CTV) was performed by the radiation oncologist,
and hence tumor properties were assigned to the entire
target region. Later the protocol was improved to also
include the segmentation of the gross tumor volume
(GTV), representing the tumor mass visible on the CT
and MRI scans. Since conductivity values in the tumor are
assumed to be higher [34], this led to more accurate, but
Fig. 3 VEDO interface displaying the predicted SAR (or temperature) distribution on top of the planning CT in all Cartesian directions. VEDO also
provides an implementation of the complaint adaptive steering approach. In addition, VEDO provides indicators to assess treatment quality based
on the simulated SAR as well as to assess the risk of overtreatment
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lower SAR predictions in the target area. Note that the
values of the dielectric properties in tumor, and their het-
erogeneity, are still unknown and subject of investigation.
Optimization and treatment quality quantifiers
In HT treatment, maximization of the target temperature,
as quantified by a range of descriptors like the median
temperature over time and space, i.e. T50 [52], is aimed
for. However, the accuracy of temperature simulations re-
quired for optimization of these quantifiers is hampered
by the strong uncertainties and variations in thermal tis-
sue properties [45]. Hence, in the current clinical routine
we use the target-hotspot quotient (THQ), or alternatively
the hotspot-target quotient (HTQ= 1/THQ) [36], since
this parameter correlated with simulated temperatures
for deep pelvic HT. THQ quantifies the mean SAR sup-
plied to the target versus the mean SAR in the highest
percentile of normal tissue, i.e. the SAR hotspots. This
parameter is used in the optimization procedure to
maximize treatment quality. In addition, we use the
SAR coverage of the target at 25 % of the maximum
value in tissue, i.e. TC25% [36]. TC25% is used to decide
whether a H&N HT treatment is possible:
-For TC25% ≥ 75 %, always a HT treatment was
prescribed.
-For TC25% in the range of 25–75 %, thermal catheters
were a requirement to verify treatment quality.
-TC25% below 25 % was interpreted as insufficient
heating and HT was not applied in these patients.
Here, we anticipated that 75 % coverage at the 25 %
iso-SAR level would be adequate to induce a sufficient
temperature rise in the entire target when taking into ac-
count thermal conduction. Note that this criterion be-
came more restrictive over time since initially tumor
properties were assigned to the entire CTV, leading to a
high electrical conductivity in the entire target and
hence also a high predicted SAR. Later, the planning
procedure was improved by assigning only a specifically
delineated GTV tumor properties and hence the SAR on
average was reduced in the CTV in some cases leading
to substantially lower TC25% values.
Pre-treatment planning controlled deep hyperthermia
using VEDO
To be able to use the simulations also for dosimetry dur-
ing treatment, we implemented the possibility to show
the estimated SAR into VEDO [36]. This SAR is calcu-
lated using the measured signals (power and phase) ap-
plied to each of the twelve channels multiplied by the
respective electric field per antenna as simulated in pre-
treatment planning. Note that, this step assumes a per-
fect SAR distribution prediction, i.e. perfect arrangement
modelling and no impact of non-modelled radiation
losses in the waterbolus, which stresses the need for
sound quality assurance.
By displaying the estimated SAR on top of the image
data (Fig. 3), the technician has a much better insight in
the applied complex interference patterns. This provides
the means for correlating locations of high SAR to hot-
spots, i.e. high measured temperatures and/or com-
plaints indicated by the patient.
Preplan adaptive hyperthermia
Initially, a library of three to six SAR distributions
were computed prior to treatment, which were up-
dated between treatments, to enable responding to
high measured temperatures and patient complaints.
This procedure required to estimate the possible com-
plaints prior to treatment. Early experience showed
that the SAR predictions not always correlated with pain
complaints indicated by the patient. Therefore, we re-
placed this procedure by our dedicated complaint-adaptive
treatment protocol for pre-plan adaptive application of
HT [53]. In this protocol, complaints by the patient or
high temperatures in normal tissue are converted by the
operator into regions where the SAR level should be de-
creased. This strategy was implemented into VEDO to re-
duce the complexity of SAR-steering. By visualizing the
SAR on top of the CT of the planning, locations of com-
plaints can be elegantly discriminated. In addition, VEDO
incorporates the information of the SAR applied to the tar-
get region. Hence, this approach provides a quantitative
basis for steering action and reduces their dependence on
the operator.
Figure 4 shows the effectivity of the complaint adap-
tive procedure in VEDO when used during H&N HT.
The coverage of the SAR pattern over the clinical target
volume (CTV, red contour) optimized using HTP, led
to a complaint at the left side of the jaw. After re-
optimization, increasing the weight of Region 3 (yellow
contour), the SAR level at the tumor reduced slightly
(15 %) but the power could be further increased, result-
ing in enhanced power deposition in the tumor. This
example also indicates that the on-line optimization ap-
proach is also an effective tool to respond on hot-spots
related to the patient specific blood perfusion pattern, as
at locations with low perfusion a moderate SAR will result
in high temperatures. With on-line SAR optimization, the
heat at these hot-spots can be reduced immediately with
still maximum energy directed to the tumor.
Current treatment procedure
Preparations and treatment planning
Initially inclusion for HT treatment is determined by the
multi-disciplinary H&N tumor board. Next pre-treatment
HTP is performed for decision making, used the thresholds
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defined before. Next the simulation results are presented
and discussed in the RT board.
Treatment and QA
Following the clinical introduction of the HYPERcol-
lar3D in 2014, this applicator is being used. Pre-
treatment planning guided HT is applied with this de-
vice up to patients tolerance for 60 min after a heating
up period of 15 min, aimed at achieving 40–43 °C
throughout the target region. Patients tolerance is de-
fined as temperatures in normal tissue above 44 °C or
pain-related discomfort indicated by the patient. In
current clinical practice, HT is added once a week to RT
applied to the primary tumor and neck levels. To
maximize the heat-induced sensitization in tumor cells
while avoiding sensitization in normal cells [14], HT
treatments are preferably applied one hour after irradi-
ation, but the time-spacing is always within three hours.
Whenever possible, closed-tip catheters are placed
interstitially under local anesthesia by a H&N surgeon,
in the tumor and/or hotspot area [35]. Additional
thermometry probes are placed on the skin. After cath-
eter placement, a CT scan (“thermometry CT”) is made
to document the location of all catheter tracts. In the
HT treatment room, the patient is placed on an ordinary
patient bed. A recently-implemented laser guided pro-
cedure is used to match patient positioning to the plan-
ning CT. Just before treatment, optical thermometry
fibers are inserted in these catheters, for monitoring
temperature in the tumor or for monitoring temperature
in surrounding normal tissues, e.g. organs at risk, hot-
spots, skin. After thermometry probes are inserted, their
exact insertion length is documented. Combined with
the documented catheter tracks of the thermometry CT,
this allows labeling temperature measurement locations,
e.g. “tumor”, “muscle”, “fat” and rigorous comparison of
measurement and simulated temperatures at exactly the
Fig. 4 Coronal views in VEDO of the predicted normalized cubic-filtered SAR (%) and temperature (°C) distributions displayed as overlay over the
CT scan. This figure shows the effectiveness of real-time adaptive treatment by adjusting the pre-optimized power absorption distributions.
Re-optimization reduced the SAR at the hotspot (Region 3, yellow contour) by 2.3-fold and the maximum temperature by 2.2 °C, while the
predicted temperature in the entire clinical target volume (CTV, red contour) was virtually unaffected, i.e. T90 reduced from 39.6 °C to 39.5 °C.
Note that, following this effective re-optimization, increase in power can be used to increase the temperatures in the target region
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same location in the patient. Additional thermometers
are placed at the inflow and outflow of the waterbolus.
After temperature sensor placement, the applicator is
placed around the target volume. Then, the water bolus
is filled with demineralized water, which is circulated at
a temperature in the range of 20–30 °C, depending on
target depth. During treatment, heart rate, power and
phase per channel and the measured temperatures are
continuously monitored and stored. After treatment, the
fiber probes and the interstitial catheters are removed.
Early clinical results
Heating quality with the HYPERcollar
The HYPERcollar applicator has been used in 48 HT
treatment series administered to 47 patients with tumors
in the oral cavity, nasopharynx, oropharynx, larynx, thy-
roid gland, trachea, hypopharynx and paranasal sinuses.
For all patients, extensive 3 dimensional (3D) treatment
plans were made using SEMCAD-X to find the optimal
position of the applicator as well as the optimal settings
of phase and amplitude per separate channel.
If their exact position is known at the mm-level, ther-
mometers placed in catheters inserted in tissue feature
the most accurate source of dosimetry data in H&N HT
treatments. However, the catheters and their placement
often are a burden to the patient and sometimes cause
morbidity. Furthermore, invasive thermometry in many
patients was not applied since the risks outweighed the
benefits [54]. Therefore, from the initiation of the pro-
ject, we focused at translating the setup from HTP to-
wards the clinic and reproduce it in every session in
order to enable reliable optimization of the SAR patterns
using HTP. In Paulides et al. [35] we showed that maxi-
mizing the SAR in the tumor is effective when striving
for higher temperatures, i.e. for the three analyzed pa-
tients high SAR values indeed correspond to high tem-
peratures (R2 = 0.59–0.94). Note that there are inherent
differences between SAR and temperature. In addition,
the uncertainties will be reduced by the novel applicator
design. The remaining sources of uncertainty, especially
the thermal properties and their variation, still need to
be addressed thoroughly for obtaining predictive simula-
tions also at the temperature level.
Clinical outcome using the HYPERcollar
In 2014, we analyzed the treatments of the subgroup of
patients with tumors that are considered to be in the
traditional H&N regions (27 patients and in total 119
treatments of one hour). The target was the CTV of RT
and the median CTV size was 63.5 ml. Delivery of
power occasionally beyond 1 kW and estimated SAR
levels (according to [36]) of on average 72.6 W/kg did
not lead to achieving 43 °C. In the 16 patients where
interstitial thermometry could be applied, we measured
target temperatures up to 38.1–42.3 °C. Hence SAR
levels up to four-fold of the SAR delivered in the pelvic
region (~16 W/kg) still in cases produced unsatisfac-
tory temperatures, which is a strong indication of the
tremendous thermoregulatory response in the H&N re-
gion as compared to other regions. Excluding the three
patients that were treated in a post-operative setting, a
response rate of 53 % was obtained [54]. This response
is very promising considering the learning curve and
the fact that this was a very unfavorable patient group,
i.e. 33 % locally advanced and 67 % re-irradiation. Im-
portantly, no severe complications or enhanced thermal
or mucosal toxicities were observed.
Preliminary analysis of heating quality with the
HYPERcollar3D
Aimed at improving the median temperatures overall,
but specifically for the nasopharynx and paranasal si-
nuses, we recently introduced the HYPERcollar3D into
the clinic. The first six patients treated with the novel
HYPERcollar3D were applied to patients suffering from
tumors of the nasopharynx [1], base of the tongue [3]
and melanoma in the parotic region [2, 55]. In these
patients, a mean forward power of 280 W (range 161–
366 W) could be applied. This exceeded our expectations
since the reduced waterbolus of the HYPERcollar3D
makes the applicator two times more efficient in power
delivery and the general average for the HYPERcollar had
been 400 W [39]. Expressed in the estimated SAR, which
is calculated using the realtime measured powers/phases
of the signals and pre-calculated electric fields [36], on
average around 72–328 W/kg was achieved. Since the
measured long-term average SAR with the HYPERcol-
lar was 75 W/kg, these data support the theoretically
predicted doubling of the applied SAR after replacing
the HYPERcollar by the HYPERcollar3D [39]. Invasive
thermometry could be applied in patient three and four.
These data indicate that SAR levels converted into
mean temperatures of 41.2 °C in the tumor (third pa-
tient) and 40.0 °C near the tumor (fourth patient), but
also up to 42.8 °C in the masseter region near the
tumor [55].
Discussion
Early analysis indicates that, despite the fact that a learn-
ing curve was observed, the HYPERcollar3D provides a
much better heating compared to the HYPERcollar.
Note that due to the learning curve, more data are re-
quired for definite conclusions about the performance of
the HYPERcollar3D using temperatures measured by in-
vasively placed thermo-probes. In addition, the HYPER-
collar3D provides a much more reproducible treatment
setup, i.e. improved positioning, more reproducible
waterbolus shape. We expect that this will improve the
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predictive value of the simulations, and will make our
simulation adaptive HT approach more effective. Based
on the predicted and measured increases in SAR and
temperatures, we anticipate that the predicted increase
in heating quality indeed converted into improved heat-
ing quality. Following the dose–response relations dem-
onstrated for other sites [56, 57], we expect that this will
also convert into improved clinical results.
In our work on deep H&N HT, we found that HTP
plays a pivotal role. First of all, it provides the tool re-
quired to quantitatively optimize treatment settings,
which inevitable to achieve sufficient treatment quality
for HT applicators with over six independent channels.
This requirement is even more pronounced when these
devices are applied in regions with an irregular outer
tissue contour where approximating the body as a
homogeneous cylinder does not hold. In addition, HTP
provides a quantitative basis for multi-disciplinary dis-
cussions to decide on inclusion, risk assessments, etc.
Before treatment, we use the predicted SAR distributions
to analyze the projected treatment quality and risk for
side effects. The positioning alignment in the HYPER-
collar3D further allows to match the RT and HT plans
to assess if enhanced RT toxicity is likely in this patient.
Simulation studies also showed that patients with a tra-
cheostoma can be treated with the HYPERcollar, as long
as the tumor is not located caudally of the tracheostoma.
This was confirmed by treatment of 2 patients with a
tracheostoma, without positioning problems and side
effects, and TC25% was sufficiently high (57 % and 64 %
in these two patients). In addition, treatment planning
provided the tool to investigate, and circumvent, the
negative effects of metal in or near the target on the
temperature distribution. Metal is standardly delineated
in the treatment planning process, and hence the effect
on the electric field distribution is taken into account.
Clinical experience confirmed that toxicity can be pre-
vented when this procedure is properly followed. In
summary, HTP plays a pivotal role in our current treat-
ment procedure. HTP allows to up front determine
treatment feasibility and risks, it stimulates cross discip-
linary discussions and it provides the means to optimize
treatment settings before and during HT application.
In the current clinical practice, fiber-optic probes
inserted into closed-tip catheters are used for assessment
of the thermal dose. Initially, in our phase I study, intra-
luminal thermometry, i.e. catheters placed in the oral
cavity or esophagus, was envisaged for monitoring target
indicative temperatures. This procedure was used in the
majority of phase III trials conducted in the H&N. For
deep pelvic HT, for example, intraluminal measurements
correlated with interstitial measurements. However,
already in the first treatment, we found that such surface
measurements in the H&N region are severely affected
by breathing, swallowing and variable tissue contact. We
therefore concluded that intraluminal measurements
provide poor dosimetry and consequently we abandoned
this method. Since then, we have used only invasively
placed catheters in which the optical thermometers are
inserted. These are not affected by poor tissue contact
and hence provide the most accurate source of informa-
tion. Unfortunately, invasive thermometry provides very
limited spatial information due to their limited number.
In addition, the sensor-catheters can usually remain only
one or two sessions [42]. Therefore we developed HTP
based dosimetry, which provides good accuracy in SAR
predictions but fail in predicting the temperature [45].
The strongly dynamic response of tissues hampers the
predictability of the temperature distribution. Hypothe-
sizing that this dynamic response is strong but relatively
stable across heated tissues, we studied if invasive
temperature measurements could be exploited to adapt
the 3D temperature simulations to match the measure-
ments. In a novel iterative tissue property reconstruction
procedure [54], we showed that optimized perfusion and
conductivity values lead to a substantial improvement in
simulation accuracy compared with the accuracy for lit-
erature values, i.e. the average absolute difference reduced
from 12.0 ± 11.7 °C (baseline values) to 0.0 ± 2.1 °C [54].
In addition, we showed that the T50 can be predicted
with a median accuracy of 0.4 °C for subsequent HT
sessions when applying thermal tissue property recon-
struction to invasive thermometry data of the first HT
session [58]. Hence, our pre-plan adaptive 3D treat-
ment planning provides the means to extrapolate sparse
thermometry into good estimates of the complete 3D
temperature distribution. This step is mandatory for
guiding highly focused target conformal delivering of a
safe and effective treatment.
Conclusions and outlook
There is now a strong evidence base for applying HT in
the H&N region. The five randomized studies all showed
significant increases in complete response and/or overall
survival, although in one study only in subgroup analysis
[28]. Combining four of the randomized and four con-
trolled non-randomized studies leads to a significant bene-
fit in favor of the addition of HT, with an odds ratio of
even 3.71. Despite these very encouraging results, unfortu-
nately the monitoring of treatment quality has been sub-
optimal in these studies. Moreover, the time between
application of RT, chemotherapy and HT was not always
recorded. From pre-clinical work, we know that the
temperature and time-delay both provide crucial factors
determining the heat-induced sensitization of tumor cells
for RT, and hence clinical outcome [13, 29]. Clinical estab-
lishing this pre-clinically determined relation critically
relies on the scoring of these factors. Hence, clinical trials
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with accurate quality control during application of hyper-
thermia are required to investigate the clinical impact of
sequencing and temperature. These data may provide op-
tions to further optimize the already impressive clinical
results. As such, treatment control is pivotal for further
developing H&N HT. The development of the HYPER-
collar3D in combination with treatment planning control
has shown to provide the required tools for accurate con-
trol and may enable studies to elucidate the parameters
crucial for further improving clinical results.
Improvements in control beyond the state-of-the-art is
envisaged by the development of magnetic imaging (MR)
guided focused microwave HT, either hybrid [59] or truly
integrated [60]. In early work, we already showed the
feasibility of this step [59] as well as the accuracy of MR
thermometry in neck equivalent gel phantoms [61]. In
addition, a recent porcine study showed the feasibility of
MR thermometry in superficial locations in the neck in
vivo in the presence of motion artifacts [62]. Hence, this
approach may provide the technology to non-invasively
provide the dose control required to maximize treatment
outcome. In addition, the treatment planning provides the
means to perform pre-treatment planning, to adapt treat-
ment settings in feedback control, and to extrapolate the
measurements to locations outside the field-of-view.
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